(PHK) PIMCO High Income Fund - Overview
Fund: Bonds, Income, Securities
Dividends
| Dividend Yield | 11.94% |
| Yield on Cost 5y | 16.00% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 90.2% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 11.7% |
| Relative Tail Risk | -7.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.73 |
| Alpha | 5.52 |
| Character TTM | |
|---|---|
| Beta | 0.259 |
| Beta Downside | 0.397 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.59% |
| CAGR/Max DD | 0.66 |
Description: PHK PIMCO High Income Fund December 01, 2025
Pharmaceutical High Income Fund (NYSE: PHK) is a U.S.-based multisector bond fund that seeks high current income by investing across a broad range of credit sectors, including high-yield corporates, emerging-market debt, and securitized assets.
Key metrics to watch: the fund’s 30-day SEC Yield is currently around 7.2%, while its weighted-average credit quality sits near BB-, reflecting a deliberate tilt toward risk-ier, higher-yielding issuers. Recent performance has been sensitive to the Federal Reserve’s policy stance-rising rates tend to compress spreads in the high-yield market, while a slowdown in the U.S. economy can boost default risk and widen those spreads.
For a deeper, data-driven dive into PHK’s risk-adjusted returns and sector exposure, you might explore the analytics on ValueRay to see how its current positioning stacks up against peers.
What is the price of PHK shares?
Over the past week, the price has changed by -0.20%, over one month by +1.60%, over three months by +4.91% and over the past year by +12.16%.
Is PHK a buy, sell or hold?
What are the forecasts/targets for the PHK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 5.9 | 18.8% |
PHK Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 763.0m USD (763.0m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 763.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 763.0m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.87% (E(763.0m)/V(763.0m) * Re(6.87%) + (debt-free company))
Discount Rate = 6.87% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)